

# Florence Nguyen-Khac

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8668748/publications.pdf>

Version: 2024-02-01

73  
papers

3,545  
citations

186265  
28  
h-index

138484  
58  
g-index

78  
all docs

78  
docs citations

78  
times ranked

5580  
citing authors

#	ARTICLE	IF	CITATIONS
1	TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis. <i>Cancer Cell</i> , 2011, 20, 25-38.	16.8	792
2	Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients. <i>Cancer Discovery</i> , 2014, 4, 1088-1101.	9.4	213
3	Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). <i>Blood</i> , 2007, 109, 3451-3461.	1.4	188
4	Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. <i>Blood</i> , 2019, 133, 1205-1216.	1.4	164
5	Drug-perturbation-based stratification of blood cancer. <i>Journal of Clinical Investigation</i> , 2017, 128, 427-445.	8.2	124
6	Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia. <i>Haematologica</i> , 2013, 98, 649-654.	3.5	119
7	MYC-containing double minutes in hematologic malignancies: evidence in favor of the episome model and exclusion of MYC as the target gene. <i>Human Molecular Genetics</i> , 2006, 15, 933-942.	2.9	116
8	Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: A systematic reappraisal of classic cytogenetic data. <i>American Journal of Hematology</i> , 2014, 89, 249-255.	4.1	113
9	Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. <i>Blood</i> , 2015, 126, 2110-2117.	1.4	94
10	Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HCV13 lympho study. <i>American Journal of Hematology</i> , 2015, 90, 197-203.	4.1	84
11	A new recurrent translocation t(11;14)(q24;q32) involving IGH and miR-125b-1 in B-cell progenitor acute lymphoblastic leukemia. <i>Leukemia</i> , 2010, 24, 1362-1364.	7.2	82
12	Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. <i>Blood</i> , 2015, 125, 856-859.	1.4	70
13	Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course. <i>Annals of Hematology</i> , 2012, 91, 863-873.	1.8	65
14	CD47 Agonist Peptides Induce Programmed Cell Death in Refractory Chronic Lymphocytic Leukemia B Cells via PLC $\beta$ 1 Activation: Evidence from Mice and Humans. <i>PLoS Medicine</i> , 2015, 12, e1001796.	8.4	65
15	Trisomy 4, a new chromosomal abnormality in Waldenström's macroglobulinemia: a study of 39 cases. <i>Leukemia</i> , 2006, 20, 1634-1636.	7.2	64
16	Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. <i>Blood</i> , 2011, 117, 6109-6119.	1.4	62
17	Gain of the short arm of chromosome 2 (2p) is a frequent recurring chromosome aberration in untreated chronic lymphocytic leukemia (CLL) at advanced stages. <i>Leukemia Research</i> , 2010, 34, 63-68.	0.8	61
18	Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. <i>Haematologica</i> , 2016, 101, 959-967.	3.5	57

#	ARTICLE	IF	CITATIONS
19	Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion. <i>Leukemia</i> , 2014, 28, 230-233.	7.2	51
20	STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. <i>Haematologica</i> , 2013, 98, 1748-1752.	3.5	50
21	The most frequent t(14;19)(q32;q13)-positive B-cell malignancy corresponds to an aggressive subgroup of atypical chronic lymphocytic leukemia. <i>Leukemia</i> , 2008, 22, 2123-2127.	7.2	47
22	EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. <i>Leukemia</i> , 2017, 31, 1547-1554.	7.2	46
23	Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. <i>Leukemia</i> , 2010, 24, 201-203.	7.2	43
24	Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. <i>Haematologica</i> , 2020, 106, 87-97.	3.5	43
25	Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1. <i>Leukemia</i> , 2017, 31, 1625-1629.	7.2	38
26	Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters. <i>Blood</i> , 2010, 116, 4588-4590.	1.4	36
27	Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference. <i>Haematologica</i> , 2016, 101, e299-e302.	3.5	35
28	Telomere dysfunction-induced foci arise with the onset of telomeric deletions and complex chromosomal aberrations in resistant chronic lymphocytic leukemia cells. <i>Blood</i> , 2010, 116, 239-249.	1.4	31
29	A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation. <i>Cancer Discovery</i> , 2019, 9, 796-811.	9.4	30
30	High frequency of clonal hematopoiesis in Erdheim-Chester disease. <i>Blood</i> , 2021, 137, 485-492.	1.4	30
31	Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies. <i>Leukemia</i> , 2012, 26, 2027-2031.	7.2	27
32	14q deletions are associated with trisomy 12, <i>NOTCH1</i> mutations and unmutated <i>IGHV</i> genes in chronic lymphocytic leukemia and small lymphocytic lymphoma. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 657-666.	2.8	25
33	IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide. <i>Annals of Hematology</i> , 2009, 88, 1215-1221.	1.8	23
34	Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. <i>Lancet Haematology</i> , 2018, 5, e82-e94.	4.6	23
35	Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort. <i>Annals of Hematology</i> , 2021, 100, 987-993.	1.8	23
36	Sex chromosome loss may represent a disease-associated clonal population in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 240-247.	2.8	22

#	ARTICLE	IF	CITATIONS
37	Cytogenetic and molecular abnormalities in <scp>W</scp>aldenstrÅm's macroglobulinemia patients: Correlations and prognostic impact. American Journal of Hematology, 2021, 96, 1569-1579.	4.1	22
38	Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. Lancet Haematology,the, 2019, 6, e470-e479.	4.6	20
39	The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations. American Journal of Hematology, 2020, 95, 1361-1367.	4.1	20
40	Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group. Genes Chromosomes and Cancer, 2018, 57, 533-540.	2.8	18
41	Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53. Blood, 2019, 134, 1821-1831.	1.4	18
42	Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients. Haematologica, 2022, 107, 593-603.	3.5	18
43	No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy. Haematologica, 2018, 103, e158-e161.	3.5	16
44	Chromosomal abnormalities in transformed Philadelphia-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of <i>JAK2</i> and the <i>TET2</i> mutations. Genes Chromosomes and Cancer, 2010, 49, 919-927.	2.8	15
45	Concomitant heterochromatinisation and down-regulation of gene expression unveils epigenetic silencing of RELB in an aggressive subset of chronic lymphocytic leukemia in males. BMC Medical Genomics, 2010, 3, 53.	1.5	15
46	Specific chromosomal IG translocations have different prognoses in chronic lymphocytic leukemia. American Journal of Blood Research, 2011, 1, 13-21.	0.6	15
47	Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia. Haematologica, 2019, 104, 1150-1155.	3.5	14
48	The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH). Leukemia, 2022, 36, 1451-1466.	7.2	14
49	Functional assessment of p53 in chronic lymphocytic leukemia. Blood Cancer Journal, 2011, 1, e5-e5.	6.2	13
50	Chronic lymphocytic leukemia: Time to go past genomics?. American Journal of Hematology, 2016, 91, 518-528.	4.1	13
51	â€œDoubleâ€•chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain. American Journal of Hematology, 2018, 93, 375-382.	4.1	13
52	Chronic lymphocytic leukaemia genomics and the precision medicine era. British Journal of Haematology, 2017, 178, 852-870.	2.5	12
53	Trisomy 4 associated with double minute chromosomes and MYC amplification in acute myeloblastic leukemia. Annales De GÃ©nÃ©tique, 2004, 47, 423-427.	0.4	11
54	Aberrant telomere structure is characteristic of resistant chronic lymphocytic leukaemia cells. Leukemia, 2010, 24, 246-251.	7.2	11

#	ARTICLE	IF	CITATIONS
55	Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance. <i>Blood Advances</i> , 2019, 3, 2920-2933.	5.2	11
56	Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug-resistant chronic lymphocytic leukemia. <i>Cancer Medicine</i> , 2019, 8, 3131-3141.	2.8	10
57	Identification of two DNA methylation subtypes of Waldenström's macroglobulinemia with plasma and memory B cell features. <i>Blood</i> , 2020, 136, 585-595.	1.4	10
58	A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial. <i>Blood</i> , 2021, 137, 1019-1023.	1.4	10
59	Burkitt-type acute leukemia in a patient with B-prolymphocytic leukemia: evidence for a common origin. <i>Cancer Genetics and Cytogenetics</i> , 2005, 159, 74-78.	1.0	8
60	Clinical and biological features of B-cell neoplasms with <i>CDK6</i> translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and <i>TP53</i> abnormalities. <i>British Journal of Haematology</i> , 2021, 193, 72-82.	2.5	8
61	Transcriptional activation of the cardiac homeobox gene <i>CSX1/NKX2-5</i> in a B-cell chronic lymphoproliferative disorder. <i>Haematologica</i> , 2008, 93, 1081-1085.	3.5	7
62	Nfkbie-deficiency leads to increased susceptibility to develop B-cell lymphoproliferative disorders in aged mice. <i>Blood Cancer Journal</i> , 2020, 10, 38.	6.2	7
63	Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization. <i>American Journal of Hematology</i> , 2021, 96, E311-E314.	4.1	7
64	Cytogenetics in the management of chronic lymphocytic leukemia: an update by the Groupe francophone de cytogénétique hémato-logique (GFCH). <i>Annales De Biologie Clinique</i> , 2016, 74, 561-567.	0.1	6
65	LHX2 deregulation by juxtaposition with the IGH locus in a pediatric case of chronic myeloid leukemia in B-cell lymphoid blast crisis. <i>Leukemia Research</i> , 2012, 36, e195-e198.	0.8	5
66	Recommendations for cytogenomic analysis of hematologic malignancies: comments from the Francophone Group of Hematological Cytogenetics (GFCH). <i>Leukemia</i> , 2020, 34, 1711-1713.	7.2	5
67	Concomitant telomere shortening, acquisition of multiple chromosomal aberrations and in vitro resistance to apoptosis in a single case of progressive CLL. <i>Leukemia Research</i> , 2011, 35, e37-e40.	0.8	3
68	“Double-Hit” Chronic Lymphocytic Leukemia, Involving the TP53 and MYC Genes. <i>Frontiers in Oncology</i> , 2021, 11, 826245.	2.8	3
69	Absence of microsatellite instability in human chronic lymphocytic leukaemia B cells. <i>Leukemia</i> , 2008, 22, 186-189.	7.2	2
70	Isolated isochromosomes i(X)(p10) and idic(X)(q13) are associated with myeloid malignancies and dysplastic features. <i>American Journal of Hematology</i> , 2019, 94, E285-E288.	4.1	2
71	Acquisition of TCF3 and CCND3 Mutations and Transformation to Burkitt Lymphoma in a Case of B-Cell Prolymphocytic Leukemia. <i>HemaSphere</i> , 2021, 5, e563.	2.7	2
72	Keeping Cell Death Alive: An Introduction into the French Cell Death Research Network. <i>Biomolecules</i> , 2022, 12, 901.	4.0	2

#	ARTICLE	IF	CITATIONS
73	Intracranial Cell Lymphomas That Mimic Meningiomas: Case Report To Understand Complex Genetic, Radiologic, and Histopathologic Entities. World Neurosurgery, 2019, 125, 339-342.	1.3	1